Document is current
Any future updates will be listed below
-
Authors
Boruah, Nabamita
Hoyos, David
Moses, Renyta
Hausler, Ryan
Desai, Heena
Le, Anh N.
Good, Madeline https://orcid.org/0009-0002-8078-808X
Kelly, Gregory
Raghavakaimal, Ashvathi
Tayeb, Maliha
Narasimhamurthy, Mohana
Doucette, Abigail
Gabriel, Peter https://orcid.org/0000-0002-3772-9669
Feldman, Michael J.
Park, Jinae https://orcid.org/0009-0001-7132-290X
Lopez de Rodas, Miguel https://orcid.org/0000-0002-6062-4064
Schalper, Kurt A. https://orcid.org/0000-0001-5692-4833
Goldfarb, Shari B.
Nayak, Anupma
Levine, Arnold J. https://orcid.org/0000-0002-1871-6387
Greenbaum, Benjamin D. https://orcid.org/0000-0001-6153-8793
Maxwell, Kara N. https://orcid.org/0000-0001-8192-4202
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA215312)
Burroughs Wellcome Fund (1017184)
- License Information
-
More Information
Article History
Received: 17 April 2024
Accepted: 30 April 2026
First Online: 21 May 2026
Competing interests
: K.A.S. reports fees for consultant services, advisor or speaker from Clinica Alemana Santiago, Shattuck Labs, AstraZeneca, Takeda, Torque/Repertoire Therapeutics, CSRlife, Agenus, Genmab, Sanofi, Parthenon Therapeutics, Bristol-Myers Squibb, Roche, Molecular Templates, Merck, PeerView, PER and Forefront Collaborative. A.J.L. is the founder and shareholder of PMV Pharma, a biotech company that works on a reactivator of mutant p53. B.D.G. has received honoraria for speaking engagements from Merck, Bristol Myers Squibb, and Chugai Pharmaceuticals; has received research funding from Bristol Myers Squibb and Merck; and has been a compensated consultant for Darwin Health, Merck, PMV Pharma, Shennon Biotechnologies, and ROME Therapeutics, of which he is a co-founder. The remaining authors declare no competing interests.
